CHOLESTATIC PRURITUS - PATHOPHYSIOLOGY AND THERAPY WITH SPECIAL CONCERN ON ITS TREATMENT WITH 5-HYDROXYTRYPTAMINE SUBTYPE-3 RECEPTOR ANTAGONISTS

被引：0
|
作者：
SCHWORER, H
RAMADORI, G
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 1995年 / 33卷 / 05期
关键词：
CHOLESTIS; LIVER; PRURITUS; ITCH; NOCICEPTION; 5-HYDROXYTRYPTAMINE; SEROTONIN; 5-HT3 RECEPTOR ANTAGONIST; ONDANSETRON; TROPISETRON;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Our current knowledge about the pathophysiology of pruritus (itch) is summarized. Special concern is given to the hypotheses to explain itch due to cholestatic liver diseases (bile acids, generation of hepatic and intestinal pruritogens, endogenous opioids). Drugs used for the treatment of cholestatic itch are discussed in detail. On the basis of successful treatment of cholestatic itch with 5-hydroxytryptamine (serotonin) subtype-3 receptor antagonists the role of serotonin in nociception is discussed.
引用
收藏
页码：265 / 274
页数：10
相关论文
共 50 条
  • [21] 5-HYDROXYTRYPTAMINE (5-HT3) RECEPTOR ANTAGONISTS .1. INDAZOLE AND INDOLIZINE-3-CARBOXYLIC ACID-DERIVATIVES
    BERMUDEZ, J
    FAKE, CS
    JOINER, GF
    JOINER, KA
    KING, FD
    MINER, WD
    SANGER, GJ
    JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (07) : 1924 - 1929
  • [22] Is There a Role for 5-HT3 Receptor Antagonists in the Treatment of Opioid-Induced Pruritus?
    Rashid, Saima
    Trivedi, Disha D.
    Al-Shathir, Mudher
    Moulton, Marie
    Baumrucker, Steven J.
    AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2018, 35 (04): : 740 - 744
  • [23] Current prevention and treatment of postoperative nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists: a review (Retraction of vol 15, pg 223, 2001)
    Hirota, Kazuyoshi
    JOURNAL OF ANESTHESIA, 2013, 27 (02) : 322 - 322
  • [24] Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome
    Zhou, Yu
    Ma, Jing
    Lin, Xingyu
    Huang, Xi-Ping
    Wu, Kaichun
    Huang, Niu
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (02) : 707 - 720
  • [25] CHARACTERIZATION AND LOCALIZATION OF A PERIPHERAL NEURAL 5-HYDROXYTRYPTAMINE RECEPTOR SUBTYPE (5-HT1P) WITH A SELECTIVE AGONIST, H-3-5 HYDROXYINDALPINE
    BRANCHEK, TA
    MAWE, GM
    GERSHON, MD
    JOURNAL OF NEUROSCIENCE, 1988, 8 (07): : 2582 - 2595
  • [26] Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy
    Okuyama, Kiyoshi
    Yoshinioto, Koichi
    Iwase, Osamu
    Ozeki, Takeshi
    Yamada, Yasuhiko
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2008, 128 (04): : 649 - 655
  • [27] Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?
    Trammel, Morgan
    Roederer, Mary
    Patel, Jai
    McLeod, Howard
    CURRENT ONCOLOGY REPORTS, 2013, 15 (03) : 276 - 285
  • [28] Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?
    Morgan Trammel
    Mary Roederer
    Jai Patel
    Howard McLeod
    Current Oncology Reports, 2013, 15 : 276 - 285
  • [29] Comparative effectiveness of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a network meta-analysis of randomized controlled studies
    Rokkas, Theodore
    Ekmektzoglou, Konstantinos
    Niv, Yaron
    ANNALS OF GASTROENTEROLOGY, 2021, 34 (04): : 535 - +
  • [30] Genetic polymorphisms in the cytochrome P450 system and efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting
    Nielsen, M.
    Olsen, N. V.
    BRITISH JOURNAL OF ANAESTHESIA, 2008, 101 (04) : 441 - 445
12345